Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1556 of 5804
-
Could early blood thinners save heart transplants?
Disease control Recruiting nowCardiac allograft vasculopathy is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. The research team is investigating whether early antiplatelet therapy post heart transplant can prevent…
Phase: PHASE3 • Sponsor: Ottawa Heart Institute Research Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Rabbit-Milk clotting drug tested for hemophilia bleeds
Disease control Recruiting nowPhase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors, 12 years of age and older, who are either on long term prophylactic treatment (e.g., emicizumab) at risk of experiencing a breakthrough bleeding event (BE), …
Phase: PHASE4 • Sponsor: American Thrombosis and Hemostasis Network • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Real-World check: does zepzelca help advanced lung cancer patients?
Disease control CompletedTo assess the effectiveness and safety of Zepzelca in adult participants with extensive stage small cell lung cancer (SCLC) in real-world clinical practice.
Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Could a shorter radiation zap before surgery be just as good for sarcoma patients?
Disease control OngoingCurrently, soft tissue sarcomas (STS) are preoperatively irradiated in a conventionally fractionated regimen of 25 x 2 Gy in five weeks. Recent radiobiological investigations, however, suggest sensitivity to (modest) hypofractionation. Within this study, patients will be randomiz…
Phase: NA • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New Dual-Action antibodies take on tough esophageal cancer
Disease control CompletedThis is a Phase II, randomized, blinded, active-controlled, global, multicenter study designed to evaluate the safety and efficacy of lomvastomig and tobemstomig, compared with nivolumab, in patients with advanced or metastatic esophageal squamous-cell carcinoma (ESCC) refractory…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New device aims to suck out deadly lung clots in major trial
Disease control Recruiting nowThe objective of this study is to evaluate real world long-term functional outcomes, safety and performance of the Indigo Aspiration System for the treatment of pulmonary embolism (PE).
Sponsor: Penumbra Inc. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New pill shows promise for Hard-to-Treat transplant complication
Disease control OngoingThis study was a single arm, open label, multicenter phase Ib / II trial in subjects with glucocorticoid refractory / dependent moderate to severe cGVHD.The trial consisted of two phases: phase I for the dose exploration and phase II for the extension study.
Phase: PHASE1, PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New shot could tame severe eczema in kids
Disease control CompletedThe purpose of this study was to assess the pharmacokinetics (PK), safety, and efficacy of nemolizumab in pediatric participants with moderate-to-severe atopic dermatitis (AD).
Phase: PHASE2 • Sponsor: Galderma R&D • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New biopsy technique could slash infection risk in prostate cancer detection
Disease control CompletedApproximately one million transrectal prostate biopsies are performed annually in the U.S., and the risk of post- biopsy infection is increasing due to greater antibiotic resistance of rectal flora. Preliminary data demonstrates that a transperineal MRI-targeted biopsy approach u…
Phase: NA • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New combo shows promise for Hard-to-Treat colorectal cancer
Disease control OngoingData from a prior phase II study of single agent cabozantinib in metastatic, refractory colorectal cancer (NCT03542877) combined with the compelling preclinical data in colorectal mouse models utilizing cabozantinib combined with nivolumab have led to this concept for a clinical …
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New study aims to sharpen epilepsy surgery decisions
Knowledge-focused Recruiting nowEpilepsy is a clinical condition that affects about fifty million people worldwide, with an estimated occurrence of 16-51 new cases per 100,000 people each year. In 60% of these patients, the origin of seizures is due to a localized (focal) alteration of the brain. In about 25 pe…
Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Glasses that shine light on postpartum depression
Symptom relief CompletedThis study will test a consumer health light therapy device (Re-Timer) for women with postpartum depression to better understand how it affects mood and the body clock (also called the circadian clock). Eligible participants will be enrolled and randomized after baseline assessm…
Phase: NA • Sponsor: University of Michigan • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC
-
New hope for rare disease: rituximab trial in malawi
Disease control OngoingThe purpose of this study is to determine the safety and efficacy of first-line, risk-stratified Rituximab-based Multicentric Castleman Disease (MCD) treatment in Malawi in a single-arm, phase II clinical trial. This study also aims to compare the cost-effectiveness of first-line…
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 16:16 UTC
-
New PET scan could help match liver transplants to right patients
Diagnosis OngoingHCC is the most common malignant liver tumor for which liver transplantation is one of the pivotal curative treatments. The best possible selection of patients who are candidates for transplantation is essential in the current context of a shortage of transplants. Performing a PE…
Sponsor: University Hospital, Lille • Aim: Diagnosis
Last updated Jul 19, 2026 00:00 UTC
-
Can we predict heart and brain trouble in diabetes patients?
Knowledge-focused Recruiting nowType 2 diabetes is a risk factor of heart failure and cognitive decline. Heart failure at its early stage is often silent. At present, primary prevention for heart failure is not available. Our aim is to identify diabetic patients at risk of heart failure in order to develop pers…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Shorter radiation before sarcoma surgery: could it reduce wound problems?
Disease control OngoingThis randomized prospective open-label phase 2 trial testes the safety and feasibility of a hypofractionated accelerated neoadjuvant proton or carbon ion radiotherapy based on the rate of wound healing disorders from beginning of radiotherapy to maximum 120 days after the planned…
Phase: NA • Sponsor: University Hospital Heidelberg • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Could a pill replace the shot for syphilis?
Disease control Recruiting nowThis study aims to evaluate the efficacy of cefixime compared to benzathine penicillin G in the treatment of syphilis.
Phase: PHASE3 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
One-Size-Fits-No-One: study tailors blood thinner length to prevent repeat clots
Disease control OngoingThe goal of this clinical trial is to evaluate tailored duration of long-term anticoagulant treatment after a first venous thromboembolism based on individualized risk assessments of recurrent VTE and major bleeding risks. Participants will be asked to fill in a questionnaire an…
Phase: NA • Sponsor: Leiden University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Liver cancer patients get Pre-Surgery combo: radiation plus immunotherapy shows promise
Disease control OngoingThis study is evaluating the safety and tolerability of neoadjuvant stereotactic body radiation therapy (SBRT) with atezolizumab and bevacizumab for treating resectable hepatocellular carcinoma. This study involves the following study interventions: * Atezolizumab * Bevacizumab…
Phase: EARLY_PHASE1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Moderna's CMV vaccine shows promise in Long-Term Follow-Up study
⭐️ VACCINE ⭐️ CompletedThe main purpose of the extension phase of this study is to evaluate the longer-term immune persistence of mRNA-1647 vaccine administered to CMV-seronegative and CMV-seropositive adults who completed Study mRNA-1647-P202 (NCT04232280). For participants in the optional booster pha…
Phase: PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:01 UTC